Autoimmune mechanisms in children with systemic lupus erythematosus

被引：4
作者：
Stichweh D. [1 ]
Pascual V. [1 ]
机构：
[1] Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, 75204, TX
来源：
Current Rheumatology Reports | 2005年 / 7卷 / 6期
关键词：
Active Systemic Lupus Erythematosus Patient; Lupus Nephritis; Mycophenolate Mofetil; Systemic Lupus Erythematosus; Systemic Lupus Erythematosus Patient;
D O I：
10.1007/s11926-005-0045-4
中图分类号：
学科分类号：
摘要：
Although the pathogenesis of SLE remains poorly under-stood, there is consensus that it involves a combination of genetic, hormonal, and environmental factors. New technologies applied to genomic and gene expression studies have revealed novel gene mutations and cytokine alterations in this disease. Recently, advances in monoclonal antibodies and recombinant DNA technology have resulted in the development of new drugs to arrest disease progres-sion and restore physiologic immune responses without major side effects. Clinical trials to test several of these novel therapies are currently underway. © 2005, Current Science Inc.
引用
收藏
页码：421 / 426
页数：5
相关论文
共 66 条
[51]  
Traynor A.E., Barr W.G., Rosa R.M., Et al., Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients, Arthritis Rheum, 46, pp. 2917-2923, (2002)
[52]  
Wulffraat N.M., Sanders E.A., Kamphuis S.S., Et al., Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus, Arthritis Rheum, 44, pp. 728-731, (2001)
[53]  
Coutts S.M., Plunkett M.L., Iverson G.M., Et al., Pharmacological intervention in antibody mediated disease, Lupus, 5, pp. 158-159, (1996)
[54]  
Wallace D.J., Tumlin J.A., LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus, Lupus, 13, pp. 323-327, (2004)
[55]  
Davis J.C., Totoritis M.C., Rosenberg J., Et al., Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus, J Rheumatol, 28, pp. 95-101, (2001)
[56]  
Kalunian K.C., Davis J.C., Merrill J.T., Et al., Treatment of systemic lupus erythematosus by inhibition of T cell costim-ulation with anti-CD154: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, pp. 3251-3258, (2002)
[57]  
Boumpas D.T., Furie R., Manzi S., Et al., A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis, Arthritis Rheum, 48, pp. 719-727, (2003)
[58]  
Merrill J.T., Erkan D., Buyon J.P., Challenges in bringing the bench to bedside in drug development for SLE, Nat Rev Drug Discov, 3, pp. 1036-1046, (2004)
[59]  
Furie R., Safety and pharmacodynamic results of a phase I single and double dose-escalation study of Lymphostat-B in SLE patients, Arthritis Rheum, 48, (2003)
[60]  
Reff M.E., Carner K., Chambers K.S., Et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, pp. 435-445, (1994)
1234567